A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses by Prow, N. et al.
ARTICLE
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Zika and chikungunya viruses have caused major epidemics and are transmitted by Aedes
aegypti and/or Aedes albopictus mosquitoes. The “Sementis Copenhagen Vector” (SCV)
system is a recently developed vaccinia-based, multiplication-defective, vaccine vector
technology that allows manufacture in modified CHO cells. Herein we describe a single-
vector construct SCV vaccine that encodes the structural polyprotein cassettes of both Zika
and chikungunya viruses from different loci. A single vaccination of mice induces neutralizing
antibodies to both viruses in wild-type and IFNAR−/− mice and protects against (i) chi-
kungunya virus viremia and arthritis in wild-type mice, (ii) Zika virus viremia and fetal/
placental infection in female IFNAR−/− mice, and (iii) Zika virus viremia and testes infection
and pathology in male IFNAR−/− mice. To our knowledge this represents the first single-
vector construct, multi-pathogen vaccine encoding large polyproteins, and offers both sim-
plified manufacturing and formulation, and reduced “shot burden” for these often co-
circulating arboviruses.
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The vaccinia vaccine (VACV) was highly immunogenic andeffective at eradicating smallpox globally, and a number ofvaccinia-based vaccines and vaccine vectors have subse-
quently been developed. For instance, a Modified Vaccinia
Ankara (MVA) smallpox vaccine, IMVAMUNE®1, was recently
approved in the European Union and Canada. We recently
described the Sementis Copenhagen Vector (SCV) vaccine tech-
nology and its application to vaccine development2. The SCV
platform was generated by deleting the D13L gene from the
Copenhagen strain of VACV. D13L encodes an essential viral
assembly protein (D13) and its deletion renders SCV incapable of
generating viral progeny in vaccine recipients2. This approach to
attenuation preserves genome amplification, thereby permitting
late phase expression of vaccine antigens from the amplified
vector genomes2. The second unique feature of the SCV vaccines
is that it can be produced in a SCV cell substrate (SCS) cell line,
which comprises Chinese hamster ovary (CHO) cells stably
expressing D13 and CP77. In trans provision of D13 allows SCV
assembly and the host-range protein, CP77, imparts VACV and
SCV multiplication capability to SCS cells2. CHO cells are widely
used in the biopharmaceutical industry, with SCV vaccine pro-
duction in the SCS cell line avoiding many of the issues associated
with vaccine manufacture in primary chicken embryo fibroblasts,
the cells traditionally used for production of vaccinia-based
vaccines2.
The SCV technology was used to develop a vaccine against
chikungunya virus (CHIKV), with the SCV chikungunya vaccine




































































































































































































































Fig. 1 SCV-ZIKA/CHIK construction, rationale and characterization. a VACV-CHIK was generated from vaccinia virus (VACV) by insertion of the CHIKV
structural protein expression cassette inserted into the A39R locus. SCV-ZIKA/CHIK was constructed from VACV-CHIK by insertion of ZIKV prME
expression cassette into the B7R-B8R locus and concurrent deletion of D13L. b After vaccination the genome is amplified in SCV-ZIKA/CHIK-infected host
cells and CHIKV and ZIKV immunogens are expressed from the amplified genomes. Due to the targeted deletion of D13L, no viral progeny are generated. c
PCR of SCV-ZIKA/CHIK and VACV infected SCS cells confirming insertion of CHIKV and ZIKV genes into A39R and B7R-B8R loci, respectively, and deletion
of D13L. d Immunoblot of SCV-ZIKA/CHIK and SCV-cont infected SCS and HeLa cells using an anti-ZIKV E antibody, with recombinant ZIKV E (rE) as a
positive control. e Immunoblot of SCV-ZIKA/CHIK and SCV-cont infected SCS and HeLa cells using a polyclonal anti-CHIKV mouse anti-serum. f Lysates
of SCV-ZIKA/CHIK-infected cells after one (P1) and ten passages (P10) in SCS cells, were analyzed by PCR (as in c) for retention of inserts in the A39R and
B7R-B8R loci. g Quantitative PCR of ZIKV M DNA of lysates described in f, normalized to VACV G1L DNA. Error bars represent standard deviation (n= 4)
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single vaccination with SCV-CHIK provided protection against
CHIKV infection and arthritic diseases in a wild-type (C57BL/6)
adult mouse model2, which recapitulates many aspects of human
CHIKV disease3,4. CHIKV is a mosquito-borne alphavirus that is
primarily associated with acute and chronic rheumatic symptoms,
with occasional infections also resulting in severe disease mani-
festations and mortality5,6. Hospitalization rates for CHIKV
patients range from ≈2.3 to ≈13%, with a 5 ± 7 day mean length
of stay (in Reunion Island)7. Although CHIKV has in the past
been associated with sporadic outbreaks around the world, in
2004 CHIKV re-emerged to produce the largest epidemic ever
recorded for this virus, with millions of cases reported globally,
primarily in Africa, Asia, and South and Central America5,6.
Autochthonous transmission has also occurred in Europe and the
USA. The primary mosquito vector species for CHIKV are Aedes
aegypti and Aedes albopictus8, both are highly invasive and, due to
human activity, have attained global distributions9.
Zika virus (ZIKV) (family Flaviviridae) represents another
mosquito-borne virus that has recently caused global health
concerns due to its association with congenital Zika syndrome
(CZS). CZS encompasses a spectrum of predominantly neurolo-
gical complications (including but not limited to microcephaly)
arising from infection of fetal brains10,11. Although infected
pregnant women often have no or only mild symptoms, the virus
appears able to cross the placenta12,13 and infect and destroy
(primarily) neural progenitor cells in the fetal central nervous
system14. Although CZS has now been well documented for the
outbreak in Brazil, there remains a question of whether similar
manifestations have gone unnoticed in Africa15. ZIKV is also
associated with Guillain-Barré syndrome. ZIKV is primarily
transmitted by Aedes aegypti mosquitoes16. Some data suggests
circulation of ZIKV in wild Aedes albopictus populations17, with
laboratory vector competence studies also suggesting ZIKV can
be transmitted by this mosquito species18. Sexual transmission of
ZIKV has also been documented, with the virus able to infect,
damage and persist in testes19.
ZIKV and CHIKV co-circulate in many parts of the world20,
with human co-infections reported in several countries21–24 and
Aedes aegypti mosquitoes are also able to co-transmit both
viruses25.
Herein we described a SCV multi-pathogen vaccine26 where a
single-vector construct encodes (from different loci) the complete
structural polyprotein cassettes of both ZIKV (prME, 2016
nucleotides) and CHIKV (C-E3-E2-6K-E1, 3747 nucleotides).
This SCV-ZIKA/CHIK vaccine provided protection against
CHIKV infection and disease in the adult CHIKV mouse model.
The vaccine also induced anti-ZIKV antibody responses in





















































































































































































Anti-ZIKV & anti-CHIKV ELISA (b)






























































Fig.2 ZIKV and CHIKV antibody responses in C57BL/6 mice and CHIKV challenge. a Timeline of vaccination, antibody assays, CHIKV challenge, viremia,
and foot measurements. b End point IgG ELISA titers against ZIKV and CHIKV 4 weeks post vaccination with 106 pfu of the indicated SCV vaccine; SCV-
ZIKA/CHIK, SCV-CHIK, or SCV-cont. The limit of detection was 1 in 30, meaning that a 1 in 30 dilution of sera was the highest (starting) concentration of
sera used in the assay. ND not detected. (n= 6, except for SCV-CHIK n= 4 mice per group). SCV-ZIKA/CHIK vaccinated mice had significantly higher
CHIKV and ZIKV titers than SCV-cont vaccinated mice (both p= 0.005, Kolmogorov–Smirnov tests). (Differences in anti-CHIKV titers between SCV-
CHIK and SCV-ZIKA/CHIK were not significant). c Neutralizing titers against ZIKVNatal and ZIKVMR766 in mice vaccinated with the indicated SCV vaccines
(n= 6 per group). Limit of detection 1 in 30. (p= 0.005 and 0.031, Kolmogorov–Smirnov tests). d Neutralizing titers against CHIKV. Limit of detection 1 in
30. (Compared with SCV-cont both p= 0.005, Kolmogorov–Smirnov tests). e Viremia of mice described in d, after challenge with CHIKV (6 weeks post
vaccination). Limit of detection 2 log10CCID50/ml. For days 1–3 the viremia in SCV-ZIKA/CHIK vaccinated mice was significantly lower than in SCV-control
vaccinated mice; all p= 0.005, Kolmogorov–Smirnov tests. f Foot swelling of mice described in e. From days 2–10 the foot swelling in SCV-ZIKA/CHIK
vaccinated mice was significantly lower than in SCV-control vaccinated mice; p= 0.03–0.001, Mann–Whitney U tests. Error bars represent standard error
of the mean
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ZIKV models: (i) survival in IFNAR−/− mice infected with the
mouse-adapted prototype African ZIKVMR766 strain of ZIKV,
which is usually lethal in these GMO animals27; (ii) fetal out-
comes in IFNAR−/− dams infected with ZIKVNatal, an unpas-
saged ZIKV isolate unequivocally associated with microcephaly27;
and (iii) testes infection and pathology in IFNAR−/− males
infected with ZIKVNatal.
Results
Design rationale for the SCV-ZIKA/CHIK vaccine. The
Copenhagen strain of VACV (VACV) was originally used as a
smallpox vaccine in Denmark and the Netherlands and provides
the source virus for SCV vaccines2. To construct SCV-ZIKA/
CHIK, VACV-CHIK was first generated by replacing the A39R
gene of VACV with the structural protein cassette of CHIKV
(Capsid-E3-E2-6K-E1) to generate VACV-CHIK (Fig. 1a) as
described2. The B7R-B8R genes of VACV-CHIK were then
replaced with the structural protein cassette of ZIKV (prME)
(Fig. 1a). (B8R encodes a secreted interferon-γ receptor homolog,
with its deletion from VACV previously shown to attenuate the
virus, whilst immunogenicity was retained28. B7R encodes a
protein found in the endoplasmic reticulum, whose deletion in
VACV resulted in smaller skin lesions in mice29). The
multiplication-defective SCV-ZIKA/CHIK was ultimately gener-
ated by concurrent deletion of the D13L gene2 (Fig. 1a).
After vaccination, SCV-ZIKA/CHIK infects host cells and the
SCV genome (which encodes the ZIKV and CHIKV immuno-
gens) is amplified (to about ≈10,000 copies30,31) (Fig. 1b). No
infectious progeny can be generated due to the absence of the
assembly protein, D132 (Fig. 1b). Late gene expression from the
amplified viral genomes then results in expression of the ZIKV
and CHIKV structural protein immunogens (Fig. 1b).
Characterization of the SCV-ZIKA/CHIK vaccine construct.
The insertion of the CHIKV genes into the A39R locus, the
insertion of the ZIKV genes into the B7R-B8R locus, and the
deletion of D13L were confirmed by PCR of SCV-ZIKA/CHIK-
infected SCS cells (Fig. 1c). Lysates of SCV-ZIKA/CHIK-infected
SCS and HeLa cells were also analyzed by immunobloting. This
illustrated expression of authentically processed, polyprotein-
derived ZIKV E (Fig. 1d) and CHIKV structural proteins (Fig. 1e)
in SCS cells (D13L-expressing cells in which SCV-ZIKA/CHIK
can generate viral progeny) and in human-derived HeLa cells
(D13L-negative cells in which SCV-ZIKA/CHIK cannot generate










































































































































































Anti-ZIKV & anti-CHIKV ELISA (b)


























































Fig. 3 ZIKV and CHIKV antibody responses in IFNAR−/− female mice and ZIKVMR766 challenge. a Timeline of vaccination, antibody assays, ZIKV
challenge, viremia and survival determinations. b End point IgG ELISA titers against ZIKV and CHIKV 4 weeks post vaccination with 106 pfu of the indicated
SCV vaccine. Limit of detection 1 in 30 dilution; ND not detected (n= 5/6 mice per group). SCV-ZIKA/CHIK vaccinated mice had higher ZIKV and CHIKV
titers than SCV-control vaccinated mice (all p= 0.009, Kolmogorov–Smirnov tests). (Differences in anti-CHIKV titers between SCV-CHIK and SCV-ZIKA/
CHIK were not significant). c Neutralization titers against ZIKVNatal and ZIKVMR766 in mice vaccinated with the indicated SCV vaccines (n= 6 per group).
(Verses SCV-cont, both p= 0.005, Kolmogorov–Smirnov tests). d Neutralization titers against CHIKV in mice vaccinated with the indicated SCV vaccines
(n= 6 per group). (Verses SCV-cont, both p= 0.005, Kolmogorov–Smirnov tests). (Differences in anti-CHIKV titers between SCV-CHIK and SCV-ZIKA/
CHIK were not significant). e Viremia after challenge with ZIKVMR766 (6 weeks post vaccination). Limit of detection 2 log10CCID50/ml. For days 2–4 the
viremia in SCV-ZIKA/CHIK vaccinated mice (n= 5/6 per group) was significantly lower than in SCV-control vaccinated mice (all p= 0.009,
Kolmogorov–Smirnov tests). Error bars represent standard error of the mean. f Survival of mice described in e. Mice were euthanized when ethically
defined end points had been reached. SCV-ZIKA/CHIK vaccinated mice survived significantly longer than SCV-control vaccinated mice (p= 0.001, log
rank, Mantel–Cox, test)
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in SCV-ZIKA/CHIK-infected HeLa cells was not lower than in
SCV-CHIK2 infected HeLa cells (Supplementary Fig. 1).
SCV-ZIKA/CHIK immunogen insert stability. To assess the
stability of the immunogen inserts, SCV-ZIKA/CHIK was pas-
saged 10 times in SCS cells (MOI= 0.01–0.001, 3 day culture per
passage), with virus from passage 1 and passage 10 analyzed by
PCR (Fig. 1f) and quantitative PCR (Fig. 1g). The correct size of
(i) the CHIKV structural protein insert into the A39R locus, and
(ii) the ZIKV prME insert into the B7R–B8R locus, was retained
after 10 passages, with no evidence of deletions (Fig. 1f). In
addition, quantitative PCR of ZIKV M protein DNA, normalized
to the G1L gene of VACV32, showed no reduction in levels of M












































































































































































































d E6.5 E12.5 E6.5 E12.5E12.5 E6.5 E12.5E6.5 E12.5 E6.5 E12.5E6.5
Placenta
Fig. 4 Challenge of vaccinated pregnant IFNAR−/− dams with ZIKVNatal. a Timeline of vaccination, antibody responses, mating, challenge, viremia, and
fetal/placental assays. b Anti-ZIKV serum IgG ELISA titers 4 weeks after vaccination with SCV-ZIKA/CHIK or SCV-cont; (p < 0.001 Kolmogorov–Smirnov
tests). c Viremia in the vaccinated mice (n= 10 per group). (For days 2–4 all p < 0.001, Kolmogorov–Smirnov tests). Error bars represent standard error of
the mean. d Fetal weights at E17.5 for SCV-vaccinated dams (n= 4–5 dams per group) infected with ZIKVNatal either at E6.5 or E12.5 (for fetuses n= 36,
33, 35, 43 left to right). SCV-cont vaccinated dams had a lower mean fetal weight than SCV-ZIKA/CHIK vaccinated dams when challenged at E6.5 (p <
0.001, t test, n= 36 and 33). Fetal/placental masses were not included in this graph. e Photographs of selected fetuses (E17.5). Highly deformed fetuses
and placenta, and fetal/placental masses are indicated by asterisks (*). The orange lines on the left represent a ruler with 1 mm marks. f Fetal and placenta
ZIKV tissue titers at E17.5 from SCV-vaccinated dams (at least three fetal/placental tissues from each of the 4/5 litters were tested); fetal heads or
placenta, except * indicating deformed fetal/placental masses. Limit of detection was 1.5 log10CCID50/g. The positive placenta in SCV-cont E6.5 group
were derived from three litters. Titers were significantly lower in the SCV-ZIKA/CHIK vaccinated groups compared to the SCV-cont groups p < 0.001
(Kolmogorov–Smirnov test) combining data from F and Pl, and E6.5 and E12.5. g qRT PCR of fetal heads. Three uninfected fetal heads (black squares) were
analyzed in triplicate and the highest value plus 3 SD was used as a cutoff (all other data points below the dashed cutoff line are not plotted to scale).
*Deformed. Statistics as for f, p= 0.001 combining data from E6.5 and E12.5
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03662-6 ARTICLE






Week 4Week 0 Week 6
ZIKVNatal




















































































































































Fig. 5 Challenge of vaccinated male IFNAR−/− mice with ZIKVNatal. a Timeline of SCV vaccination, challenge, viremia and testes examinations. b Anti-ZIKV
serum IgG ELISA titers 4 weeks after vaccination with SCV-ZIKA/CHIK or SCV-cont (p < 0.001, Kolmogorov–Smirnov test). c Viremia in SCV-vaccinated
mice after challenge with ZIKVNatal (n= 10 mice per group) (days 2–4 all p < 0.001, Kolmogorov–Smirnov tests). Error bars represent standard error of the
mean. d Pictures of testes taken day 21 after challenge. *One testes (out of 12) was slightly smaller, another showed signs of hemorrhage (arrow). The
orange line on the left represents a ruler with 1 mm marks. e H&E staining of testes from SCV-cont vaccinated mice showing dark patches of cellular
infiltrates (arrows); top row bar= 5mm. Enlargements of selected areas show (in white circles, left to right) hemorrhage around Leydig cells (in the same
testes arrowed in d), high density of inflammatory infiltrates in and around the seminiferous tubules, and destruction of seminiferous tubules; bottom row,
bar= 200 μm (left) and bars= 1 mm (2 right hand images). f H&E staining of testes from SCV-ZIKA/CHIK vaccinated mice. Enlargements of selected
areas show normal testis architecture with no discernible lesions. Bars as in e. g Immunohistochemistry with 4G4 (anti-NS1 monoclonal antibody) of serial
sections of the three testes shown top left in e. Bar= 5mm. h Immunohistochemistry with 4G4 of serial sections of the three testes shown top left in f. Bar
= 5mm. i ZIKV RNA qRT PCR of testes day 21 post infection. SCV-ZIKA/CHIK vs SCV-cont, p= 0.003 (Kolmogorov–Smirnov test); (n= 6/7 testes from
6/7 mice per SCV vaccine group). Three uninfected negative control testes from three mice and one known positive control sample were included
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Fig. 6 Effects of prior CHIKV or VACV infections on SCV-ZIKA/CHIK vaccination. a Timeline of CHIKV infection, SCV vaccination and determination of
antibody responses to ascertain whether prior CHIKV infection affects anti-ZIKV responses after SCV-ZIKA/CHIK vaccination. b Mice were infected with
CHIKV or were mock infected with PBS and anti-CHIKV antibody titers determined 5 weeks post infection by ELISA (n= 6 mice per group). c Mice that
had been infected with CHIKV were vaccinated with SCV-ZIKA/CHIK and after 4 weeks anti-CHIKV and anti-ZIKV serum ELISA titers were determined.
Sera from mice vaccinated with SCV-cont were included in the assays as negative controls. dMean anti-ZIKV serum ELISA titers 4 weeks after SCV-ZIKA/
CHIK vaccination in the indicated groups (n= 6, 6, 15, 10, left to right), either with prior CHIKV infection (+) or without (−). Error bars represent standard
error of the mean. e Box and whiskers plots using the same data from d to compare anti-ZIKV ELISA titers obtained in mice that had previously been
infected with CHIKV (+) (n= 6) with those that had not (−) (n= 31). Box—upper and lower quartile, with bar as median. Whiskers—maximum and
minimum values. f Timeline of VACV infection, SCV vaccination and determination of antibody responses to ascertain whether prior VACV infection
affects anti-ZIKV and anti-CHIKV responses after SCV-ZIKA/CHIK vaccination. g VACV responses after VACV infection or mock infection (PBS). h Anti-
ZIKV ELISA titers obtained in mice that had previously been mock infected or infected with VACV. Also shown are responses after SCV-ZIKA/CHIK
vaccination in mice that had previously received a VACV or mock infection. Limit of detection 1 in 30 dilution. i As for h except measuring anti-CHIKV
ELISA titers. j Timeline of vaccinations and ELISAs to ascertain whether prior SCV-CHIK vaccination affects anti-ZIKV and anti-CHIKV responses after
SCV-ZIKA/CHIK vaccination. k Anti-ZIKV ELISA titers obtained in mice that had previously been mock infected or vaccinated with SCV-CHIK and then
vaccinated with SCV-ZIKA/CHIK. l Anti-CHIKV ELISA titers obtained in mice that had previously been mock infected or vaccinated with SCV-CHIK and
then vaccinated with SCV-ZIKA/CHIK (statistics by t test)
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Vaccination of C57BL/6 mice and CHIKV challenge. The
timeline of vaccination, challenge and analyses is shown in
Fig. 2a. SCV-ZIKA/CHIK, SCV-CHIK2, and SCV-cont (control
SCV vector encoding DsRed2) were produced in SCS cells. The
SCV vaccines were used to vaccinate C57BL/6 mice once (106
pfu) by the intramuscular route (Fig. 2a, week 0). Four weeks after
vaccination, anti-ZIKV and anti-CHIKV IgG titers were deter-
mined by ELISA. SCV-ZIKA/CHIK, but not SCV-CHIK (or
SCV-cont), induced significant antibody responses to ZIKV
(Fig. 2b, anti-ZIKV), whereas both SCV-ZIKA/CHIK and SCV-
CHIK (but not SCV-cont) induced significant responses to
CHIKV (Fig. 2b, anti-CHIKV). SCV-ZIKA/CHIK, but not SCV-
CHIK (or SCV-cont), also induced significant neutralizing
responses to both ZIKVNatal and ZIKVMR766 (Fig. 2c), with both
SCV-ZIKA/CHIK and SCV-CHIK inducing neutralizing anti-
body responses to CHIKV (Fig. 2d).
Vaccinated mice were challenged with CHIKV 6 weeks after
vaccination (Fig. 2a, week 6). Both SCV-ZIKA/CHIK and SCV-
CHIK vaccinated mice were protected against the development of
a detectable CHIKV viremia (Fig. 2e) and the ensuing foot
swelling (Fig. 2f), which is a measure of CHIKV-induced
arthritis4.
Vaccination of IFNAR−/− mice and ZIKVMR766 challenge. The
timeline of vaccination, challenge and analyses is shown in
Fig. 3a. Significant anti-ZIKV ELISA titers were seen after a single
SCV-ZIKA/CHIK vaccination of IFNAR−/− mice (Fig. 3b, anti-
ZIKV) and significant anti-CHIK ELISA titers were seen after
SCV-ZIKA/CHIK and SCV-CHIK vaccination (Fig. 3b, anti-
CHIKV). Significant anti-ZIKVNatal and ZIKVMR766 neutralizing
titers were also seen after SCV-ZIKA/CHIK vaccination (Fig. 3c),
and significant anti-CHIKV neutralizing titers were seen after
SCV-ZIKA/CHIK and SCV-CHIK vaccination (Fig. 3d).
After challenge with ZIKVMR766, SCV-ZIKA/CHIK vaccinated
mice showed no detectable viremia (Fig. 3e) and showed 100%
protection against mortality, whereas SCV-CHIK and SCV-cont
vaccinated mice developed severe disease and were killed (Fig. 3f).
SCV-ZIKA/CHIK vaccination thus provided complete protection
against challenge with the generally lethal ZIKVMR766 strain of
ZIKV27.
Vaccination of IFNAR−/− dams and ZIKVNatal challenge. The
timeline of vaccination, challenge and analyses is shown in
Fig. 4a. Following a single SCV-ZIKA/CHIK vaccination, sig-
nificant anti-ZIKV ELISA titers were seen in female IFNAR−/−
mice (Fig. 4b). Mice were then mated and after plug detection
were weighed; if weight increased by >1 g at E6.5 (confirming
pregnancy), dams were challenged with ZIKVNatal (at E6.5 or
E12.5, nominally representing early and mid gestation, respec-
tively). Viremia was significantly and substantially suppressed in
SCV-ZIKA/CHIK vaccinated dams compared to SCV-cont vac-
cinated dams (Fig. 4c). ZIKVNatal infection was previously
reported to be asymptomatic in IFNAR−/− female mice >8 weeks
old27, and no symptoms were seen in infected dams in the current
study.
At E17.5, dams were euthanized and fetal weights determined.
SCV-ZIKA/CHIK vaccinated dams infected at E6.5 had fetuses
with significantly higher weights at E17.5 when compared to
SCV-cont vaccinated dams (t test, p < 0.001) (Fig. 4d, E6.5). Fetal
weights were on average 17.3 % lower (0.8 ± SE 0.032 g, n= 33) in
SCV-cont vaccinated dams when compared to SCV-ZIKA/CHIK
vaccinated dams (0.97 ± SE 0.022 g, n= 36). (In humans birth
weights are also often lower for neonates from ZIKV infected
mothers33). The weight difference in the murine fetuses was not
due to litter size differences as litter sizes were actually slightly
larger in the SCV-ZIKA/CHIK vaccinated dams (8, 9, 9, and 10)
compared with the SCV-cont vaccinated dams (7, 7, 9, 10)
(Fig. 4d, E6.5, left to right). Fetal weights were not significantly
different when dams were infected at E12.5; (litter sizes where 8,
11, 10, 10 and 8, 10, 11, 11, 9, Fig. 4d, E12.5 left to right).
Photographs of selected fetuses are shown in Fig. 4e, with the
deformed fetuses and fetal/placental masses in the SCV-cont
vaccinated animals indicated (Fig. 4e, *). Fetuses, placenta and
fetal/placental masses were either analyzed for viral titers (Fig. 4f)
or where subject to qRT PCR (Fig. 4g), with no virus or viral RNA
detected in tissues from SCV-ZIKA/CHIK vaccinated mice.
Vaccination of IFNAR−/− males and ZIKVNatal challenge. The
timeline of vaccination, challenge and analyses are shown in
Fig. 5a. Following a single vaccination of IFNAR−/− male mice
with SCV-ZIKA/CHIK, significant anti-ZIKV ELISA antibody
responses were generated (Fig. 5b). SCV-ZIKA/CHIK vaccinated
mice also showed a significant and substantial reduction in vir-
emia after challenged with ZIKVNatal (Fig. 5c). On day 21 after
challenge mice were euthanized and testes removed. Testes from
SCV-cont vaccinated mice were overtly normal except one testis
(out of 12, n= 6 mice per group) was slightly smaller (Fig. 5d, *)
and another showed signs of hemorrhage (Fig. 5d, arrow).
Histology of testes from SCV-cont vaccinated mice (n= 6
mice, 1 testis from each mouse) showed lesions (hemorrhage,
infiltrates and/or destruction of seminiferous tubules34) in 5/6
testes (from six mice) (Fig. 5e). In contrast, none of the testes
from SCV-ZIKA/CHIK vaccinated mice (n= 7 mice, 1 testis
from each mouse) showed any discernible lesions (Fig. 5f).
Immunohistochemistry with 4G4 (pan-flavivirus anti-NS1 anti-
body27) illustrated strong staining in and around the lesions, with
staining primarily localizing to seminiferous tubules (Fig. 5g;
serial sections of the three testes shown top left in e). In contrast,
testes from SCV-ZIKA/CHIK vaccinated mice showed minimal
staining (Fig. 5h; serial sections of the three testes shown top left
in f).
qRT PCR of the testes showed a significantly lower (p= 0.003,
Kolmogorov–Smirnov test) level of ZIKA RNA in the testes from
SCV-ZIKA/CHIK vaccinated mice compared with testes from
SCV-cont mice (Fig. 5i). Levels in testes from SCV-ZIKA/CHIK
vaccinated mice were no higher than those in uninfected mice
(Fig. 5i), suggesting complete clearance of ZIKV RNA in testes
from the former animals (mice were killed on day 21 after
infection and for each SCV-vaccinated mouse, one testis was used
for histology and the other for qRT PCR).
SCV-ZIKA/CHIK vaccination after CHIKV or VACV or SCV-
CHIK. One might speculate that the ability of SCV-ZIKA/CHIK
vaccination to induce anti-ZIKV responses might be compro-
mised in individuals that have anti-CHIKV-immune responses
due to a prior exposure to CHIKV35,36. To test this contention,
C57/BL6 mice were infected with CHIKV and were then vacci-
nated with SCV-ZIKA/CHIK (Fig. 6a). After CHIKV infection,
mice showed robust anti-CHIKV ELISA IgG responses (Fig. 6b),
and after SCV-ZIKA/CHIK vaccination these responses increased
(Fig. 6c, anti-CHIKV). Importantly, in CHIKV-immune mice,
SCV-ZIKA/CHIK vaccination efficiently generated anti-ZIKV
responses (Fig. 6c, anti-ZIKV). These latter responses were not
significantly different from those obtained in mice with no prior
CHIKV infection, when comparing either means (Fig. 6d) or
medians (Fig. 6e). Anti-ZIKV antibody induction by SCV-ZIKA/
CHIK was thus not compromised by pre-existing anti-CHIKV
immunity.
Anti-vector immunity can compromise the ability of a
recombinant vaccine vector effectively to induce immune
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responses. To test this for SCV, mice were either mock infected or
infected with VACV (Fig. 6f), with the latter mice shown to have
generated anti-VACV antibody responses (Fig. 6g). Mice were
then vaccinated with SCV-ZIKA/CHIK and anti-ZIKV and anti-
CHIKV ELISA titers determined (Fig. 6f). Neither anti-ZIKV
(Fig. 6h) nor anti-CHIKV antibody responses (Fig. 6i) were
significantly affected by prior VACV infection. These results are
consistent with studies using recombinant MVA vaccines37,38 and
argue that pre-existing anti-VACV immunity does not effectively
suppress the ability of these poxvirus vaccines to induce antibody
responses to recombinant immunogens. Prior vaccination with
SCV-CHIK also did not significantly affect anti-ZIKV responses
following SCV-ZIKA/CHIK vaccination (Fig. 6j,k), although anti-
CHIKV responses were significantly boosted (Fig. 6l).
Discussion
Herein we describe the application of the SCV vaccine technology
to the development of a single vector, multi-pathogen, SCV-
ZIKA/CHIK vaccine. The vaccine was able to prevent viremia and
arthritic disease in a CHIKV wild-type mouse model and to
mediate protection in three models of ZIKV infection using
IFNAR−/− mice. A single vaccination protected against (i) lethal
infection with ZIKVMR766, (ii) fetal/placental ZIKVNatal infection
in pregnant IFNAR−/−dams, and (iii) ZIKVNatal infection and
testes damage in male IFNAR−/− mice.
Vaccinia-based vaccines have a number of features that make
them attractive for managing epidemics in resource poor settings,
primarily cold chain-independent distribution capacity39 and
long lasting immunity40. The inability of SCV vaccines to gen-
erate viral progeny in human cells or to cause disease in immu-
nodeficient mice2 suggests SCV will have a similar safety profile
as the replication-deficient, passage-attenuated MVA. MVA has
an impeccable safety record, with more than 120,000 people
vaccinated at the end of the smallpox eradication campaign
without any serious adverse effects41. In addition, MVA was
recently shown to be safe and well tolerated in individuals with
atopic dermatitis or HIV42,43. The CHO-based SCS line also
provides a rapid production and scale up capacity for SCV vac-
cine manufacture2.
Prior exposure to CHIKV did not significantly affect the ability
of SCV-ZIKA/CHIK to induce antibody responses to ZIKV.
Concepts related to “original antigenic sin”35 might raise con-
cerns that pre-existing immune responses to CHIKV could
inhibit induction of anti-ZIKV responses. However, the ZIKV
and CHIKV polyproteins are expressed from separate loci in the
SCV-ZIKA/CHIK vaccine, with these two immunogens not
physically linked, a prerequisite for the classically described “sin”
phenomenon35. Concerns that pre-existing anti-CHIKV cytotoxic
T cell (CTL) responses44 might kill SCV-ZIKA/CHIK-infected
cells before sufficient ZIKV antigens can be made, might be
ameliorated by the recent insight that CTL killing activity in vivo
is actually rather limited45, with poxviruses also deploying a
plethora of strategies to inhibit apoptosis46. Prior infection with
VACV had no significant impact on anti-ZIKV and anti-CHIKV
antibody induction after SCV-ZIKA/CHIK vaccination, an
observation consistent with studies on recombinant MVA vac-
cines37,38. Prior SCV-CHIK vaccination also had no significant
impact on anti-ZIKV antibody induction after SCV-ZIKA/CHIK
vaccination. Vaccinia deploys a series of strategies to avoid
antibody neutralization47, and human studies have illustrated that
although anti-VACV immunity effectively inhibits VACV dis-
semination, it is much less effective at inhibiting initial infection
by VACV48. SCV vaccines do not disseminate in vivo2, with a
single round infection sufficient to induce immunity.
When comparing the anti-CHIKV responses after SCV-ZIKA/
CHIK and SCV-CHIK, no consistent significant difference was
observed (for Figs. 2d and 3b,d, p= 0.06–0.3,
Kolmogorov–Smirnov tests). Furthermore, anti-ZIKV antibody
responses after SCV-ZIKA/CHIK and SCV-ZIKA vaccination
were also not significantly different (Supplementary Fig. 2).
Interference or interaction effects between the ZIKV and CHIKV
immunogens thus appear to be minimal in this context.
To the best of our knowledge this represents the first effica-
cious single vector, multi-pathogen vaccine that encodes whole
structural polyprotein gene cassettes from two unrelated viruses.
The large payload capacity of poxvirus vectors (at least 25,000
bp49) is relatively unique, with most established virus vector
systems unable to package genomes containing such large
recombinant inserts. An immunogenic multi-pathogen VACV
construct has previously been reported and encoded (from three
insertion sites) single antigens from influenza, hepatitis B, and
herpes simplex virus50. A recently reported multi-pathogen MVA
vaccine, encoding hepatitis B and rabies virus immunogens under
the control of a T7 promoter, required co-infection with a MVA
encoding T7 polymerase, but failed to induce responses to the
heterologous immunogens51. A trivalent MVA vaccine encoding
three H5N1 influenza hemagglutinin genes was efficacious and
used three different promoters and a single-insertion site52.
Herein we used the poxvirus synthetic strong early late pro-
moter53; one to drive CHIKV, and another to drive ZIKV,
polyprotein expression. Despite the potential for homologous
recombination, the SCV-ZIKA/CHIK construct remained stable
over 10 passages. As these two identical 39 nucleotide long pro-
moters are widely separated in the SCV genome, any intramo-
lecular homologous recombination would delete the ≈21 kb of
SCV genome sequence that lies between the A39R and B7R-B8R
loci. This would result in a virus whose propagation in SCS cells
would be non-viable due to the loss of ORFs coding for essential
viral proteins.
Multi-pathogen vaccines can also be generated by delivering
epitopes from multiple pathogens54,55; however, generating
antibody responses to complex folded immunogens using such an
approach is intrinsically difficult. An alternative approach is
mixing, such as the recently developed hexavalent childhood
vaccine (DTaP5-IPV-Hib-HepB)56. Another mixed vaccine is the
tetravalent dengue vaccine, which compromises a mixture of four
chimeric viral constructs covering the four dengue serotypes57. A
SCV-ZIKA/CHIK vaccine would (like such mixed vaccines)
reduce the “shot burden” and simplify immunization schedules.
In addition, the single-vector construct simplifies manufacture,
ensures equal delivery of immunogen genes to antigen producing
cells in vivo, and avoids formulation issues associated with
mixing.
Methods
Ethics statement. All mouse work was conducted in accordance with the “Aus-
tralian code for the care and use of animals for scientific purposes” as defined by
the National Health and Medical Research Council of Australia. Animal experi-
ments and associated statistical treatments were reviewed and approved by the
QIMR Berghofer Medical Research Institute animal ethics committee (P2195,
A1604-611M) and CHIKV work was conducted in biosafety level-3 facility at the
QIMR Berghofer.
Cell lines and virus stocks. CHO cells (ATCC CCL-61) were used to generate the
SCS cell line2. Vero (ATCC CCL-81) and C6/36 cells (ATCC CRL1660) were
purchased from the European Collection of Authenticated Cell Cultures/Sigma in
2016 and were passaged no more than 20 times. Cell lines are routinely authen-
ticated in-house by Short Tandem Repeat profiling and checked for mycoplasma
using MycoAlert™ Mycoplasma Detection Kit (Lonza). Virus stocks were checked
for mycoplasma as described58. Low endotoxin contamination status of fetal calf
serum was confirmed as described59.
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Construction of SCV-ZIKA/CHIK. The construction of VACV-CHIK from the
Copenhagen strain of vaccinia (gifted by Dr Robert Drillien, Institute of Virology,
Strasbourg, France) has been described previously2. SCV-ZIKA/CHIK was con-
structed by replacing the B7R-B8R ORF with a poxvirus expression cassette for
ZIKV prME (Brazilian isolate ZikaSPH2015, Genbank: KU321639) and deleting
the D13L ORF by homologous recombination (Fig. 1a). For insertion of the ZIKV
prME expression cassette (by replacing the B7R-B8R ORFs), a homologous
recombination cassette was constructed consisting of the following elements: (i) F1
homologous recombination targeting sequences upstream of the B7R gene, (ii) an
expression cassette consisting of a vaccinia virus early/late promoter53 operatively
linked to a protein coding sequence for a fluorescent blue protein fusion with
Zeocin resistance protein (BFPzeo) and ending with a poxvirus early transcriptional
stop sequence, (iii) a repeat of the F1 homologous recombination arm, (iv) an
expression cassette consisting of a vaccinia virus early/late promoter operatively
linked to a protein coding sequence for ZIKV prME followed by a poxvirus early
transcriptional stop sequence and finally (v) F2 homologous recombination tar-
geting sequences downstream of the B8R gene. The signal sequence for prME was
the natural predicted sequence, which constitutes the C-terminal 18 amino acids of
Capsid60. With the addition of the ATG start codon, the N-terminal sequence of
prME becomes MGADTSVGIVGLLLTTAMA-AEVTRR (italics represents the
beginning of pr). The nucleotide sequences of the ZIKA and CHIK immunogens
and insertion sites, and the D13L deletion (see below) are provided in Supple-
mentary Fig. 3.
The D13L ORF was replaced by DsRed/CP7761 (Fig. 1a) as described in the
construction of SCV-CHIK2. Homologous recombination was performed by
transfecting both the ZIKV prME and D13L homologous recombination cassettes
into CHO+D13L cells2 previously infected with VACV-CHIK at an MOI of 0.01
PFU/cell. SCVDsRed/CP77-ZIKABFPzeo/CHIK was enriched from the homologous
recombination infection by amplifying the virus in CHO+D13L cells in the
presence of Zeocin (ThermoFisher Scientific) followed by a second infection of a
fresh set of CHO+D13L cells in the presence of Zeocin with amplified virus. These
infected cells were recovered and made into a single cell suspension by TrypLE
Select digestion and then single cell sorted so that a single blue and red fluorescent
cell was seeded into one well of a 96-well plate containing CHO+D13L cells using
FACSAria Fusion flow cytometer (BD Biosciences). After incubation in the
presence of Zeocin, wells containing a single blue and red fluorescent focus of
infection were harvested and resuspended as single cell suspensions before single
cell sorting and seeding into 96-well plates of fresh CHO+D13L cells. This single
cell sorting and culturing in the presence of Zeocin was repeated five times in order
to eliminated trace contamination with the original VACV-CHIK and produce
clonal SCVDsRed/CP77-ZIKABFPzeo/CHIK. A number of clonally purified SCVDsRed/
CP77-ZIKABFPzeo/CHIK vectors were amplified in SCS cells in the absence of
Zeocin and were then subject to PCR analysis to confirm insertion of ZIKV prME
into the B7R-B8R locus, retention of the CHIK expression cassette in the A39R
locus, removal of D13L and absence of contaminating VACV-CHIK. Clones were
amplified in SCS cells in the absence of Zeocin to encourage intramolecular
recombination between the F1 homologous recombination sequence and the F1
repeat sequence resulting in the deletion of both BFPzeo and DsRed/CP77
expression cassettes. Single cell suspensions of these cultures were bulk sorted
(FACSAria) and non-fluorescent cells retained. The PCR was repeated to confirm
retention of inserts, removal of D13L, and loss of BFPzeo and DsRed/CP77. All SCV
vaccine stocks were prepared in SCS cells and titred as described2.
PCR of SCV-ZIKA/CHIK-infected SCS cells. Construction and purity of SCV-
ZIKA/CHIK was confirmed by PCR. SCS cells were infected with SCV-ZIKA/
CHIK (MOI= 1) and after 24 h DNA was extracted using a DNAeasy kit (Qiagen).
PCR reactions were performed using KAPA HiFi polymerase (Kapa Biosystems)
with the following primer pairs: A39R locus, forward 5′-GTCGTA-
CAATTCTGTACCTATCAAGG-3′ and reverse 5′-CGCATCTGTATCAAACG-
GAGG-3′; B7R-B8R locus, forward 5′-GGTGCTTCGTACATAAGTTGT-3′ and
reverse 5′-GGAATCACTATTACTACTTGT-3′; and D13L locus, forward 5′-
CGACACCCGTTTCATGGAACAA-3′ and reverse 5′-GGACGACGAGA-
TACGTAGAGTGT-3′. PCR products were run on a 1% agarose gel and visualized
using GelRed (Biotium). Uncropped images are provided in Supplementary Fig. 4.
Western blotting of SCV-ZIKA/CHIK-expressed immunogens. Western blot-
ting of CHIKV antigens in lysates of SCV-ZIKA/CHIK-infected SCS cells (24 h,
MOI= 1) and HeLa cells (MOI= 5) at the indicated time(s) was undertaken as
described previously using anti-CHIKV polyclonal anti-sera2 (1 in 100 dilution)
generated in-house by immunizing C57BL/6 mice twice with inactivated CHIKV.
The lysates were also analyzed using an anti-ZIKV E protein mouse polyclonal
serum, generated in-house by immunization with E. coli-derived purified recom-
binant ZIKV E protein formulated with Titremax Gold adjuvant (Sigma-Aldrich).
Uncropped images are provided in Supplementary Fig. 4.
Assessment of SCV-ZIKA/CHIK insert stability. SCV-ZIKA/CHIK was pas-
saged ten times in subconfluent SCS cells, with 3 days of culture for each passage.
After each culture period, cells were collected by scraping and were homogenized
(as described2) and reseeded at MOI= 0.01–0.001. The MOI was estimated by
plaque formation in SCS cells. PCR of infected cells after passage 1 and passage 10
was performed for the A39R and B7R-B8R loci on cell lysates as described above.
For quantitative PCR, DNA was extracted from lysates using the Magery Nagel
Nucleospin tissue extraction kit (Scientifix, Vic, Australia). ZIKV M primers were F
3′ TTGGTCATGATACTGCTGATTGC 5′, R 3′ CCTTCCACAAAGTCCCTA-
TTGC 5′ and VACV G1L primers were F 3′ TCGGTGTCTATAACGGAAC 5′, R
3′ GTTTAGTCGTGTCTACAAAAGG 5′. Quantitative PCR was undertaken (in
duplicates) using the CFX 96 touch PCR detection system (Biorad) using the same
cycling parameters for both sets of primers; 1 × 50 °C 2min, 1 × 95 °C 2min, 45 ×
94 °C 5 s, 52 °C 10 s and 72 °C 40 s), with analysis using Biorad CFX Real Time
Analysis software.
Vaccination and antibody responses. Groups of male or female (as indicated)
6–8-week-old C57BL/6J (ARC, Canning Vale, WA, Australia) or IFNAR−/− mice27
were vaccinated intramuscularly (50 μl into both quadriceps femoris muscles) with
SCV-CHIK, SCV-ZIKA/CHIK or SCV-cont (a control SCV vaccine encoding
dsRed2) in 10 mM Tris HCl pH 8. Serum antibody responses were determined by
standard ELISA using (i) whole inactivated CHIKV as antigen as described62 and
(ii) whole-ZIKVMR766 virus preparations purified from infected Vero cell super-
natants by 8% polyethylene glycol precipitation and ultracentrifugation through a
20% sucrose cushion. CHIKV neutralization titers against the Reunion Island
isolate (LR2006-OPY1) of CHIKV were determined as described63. As ZIKVNatal
plaques poorly, ZIKV neutralizing antibody titers were determined (against
ZIKVNatal and ZIKVMR766) by incubating dilutions of heat-inactivated mouse
serum (in duplicate) with 100 CCID50 of virus for 3 h before adding Vero E6 cells
(Sigma, ECACC Vero C1008) (104/well of a 96-well plate). After 5 days cells were
fixed, stained with crystal violet and the reciprocal 50% neutralizing titers
determined.
CHIKV and ZIKV challenge. Vaccinated C57BL/6 mice were challenged with 104
CCID50 of the Reunion Island CHIKV isolate subcutaneously into the feet, and the
post-challenge viremia and foot swelling determined as described4,63. Vaccinated
IFNAR−/− mice were challenged by s.c. infection with 103 CCID50 of ZIKVMR766
or 104 CCID50 ZIKVNatal and viremia assessed as described27. ZIKVMR766 infected
female IFNAR−/− mice were killed when ethically defined end points were reached
(primarily hind-limb paralysis). ZIKVNatal infection of pregnant IFNAR−/− dams
was undertaken at E6.5 or E12.5 with viremia in dams measured as described27. At
E17.5 dams were euthanized, fetuses weighted and photographed, and fetal heads
and placenta were either (i) processed for determination of tissue titers27 or (ii)
placed into RNAlater (Ambion, Austin TX, USA) and processed for qRT PCR63
using ZIKV M primers (as described above), with normalization to RPL13A27.
Male IFNAR−/− mice were infected with ZIKVNatal and viremia determined as
described27. On day 21 post infection testes were removed and analyzed for qRT
PCR as above, and H&E staining as described3. Immunohistochemistry was
undertaken using the 4G4 monoclonal antibody generated in-house (and used as
neat hybridoma supernatant) as described27,64 and Warp Red Chromogen kit
(Biocare Medical, CA, USA).
Prior infection with VACV, CHIKV or SCV-CHIK. Female 6–8-week-old C57BL/6
mice were infected with VACV (replication competent Copenhagen strain of
vaccine) 106 pfu i.p. or with CHIKV (LR2006-OPY1) 104 CCID50 s.c. in the feet4 or
with SCV-CHIK 106 pfu i.m.
Statistics. Statistical analysis of experimental data was performed using IBM SPSS
Statistics for Windows, Version 19.0. Two-sample comparison using t test was
performed when the difference in variances was <4, skewness was ≥2 and kurtosis
was <2. Non-parametric data with difference in variances of <4 was analyzed using
Mann–Whitney U test, if difference of variances was >4 the Kolmogorov–Smirnov
test was employed. The log rank (Mantel–Cox) test was used for statistical analysis
of surviving proportions.
Data availability. The authors declare that the data supporting the findings of this
study are available with the article and its Supplementary Information files, or are
available from the authors upon request.
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